Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

NCT07303881 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

IrAE
Hematologic Disorder
Lung Cancer (Locally Advanced or Metastatic)

Interventions

DRUG: golidocitinib

Sponsor

The First Affiliated Hospital of Guangzhou Medical University